Taysha Gene Therapies Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Taysha Gene Therapies (TSHA) PT Lowered to $31 at Jefferies
April 1, 2022 8:46 AM EDTJefferies analyst Eun Yang lowered the price target on Taysha Gene Therapies (NASDAQ: TSHA) to $31.00 (from $41.00) while maintaining a Buy rating.
The analyst commented, "Prioritization of several key pipeline programs is positive (vs prior >20 gene therapy programs in development),... More
Taysha Gene Therapies (TSHA) Misses Q4 EPS by 7c
March 31, 2022 7:35 AM EDTTaysha Gene Therapies (NASDAQ: TSHA) reported Q4 EPS of ($1.32), $0.07 worse than the analyst estimate of ($1.25).
For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.
... More